# DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria

> **NCT02450578** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 22 (actual)

## Conditions studied

- Plasmodium Falciparum, Malaria

## Interventions

- **DRUG:** DSM265 400mg
- **DRUG:** Placebo to DSM265 400 mg
- **BIOLOGICAL:** Plasmodium falciparum sporozoite challenge
- **DRUG:** Malarone

## Key facts

- **NCT ID:** NCT02450578
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450578, "DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02450578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*